DMK
BCRX icon

David M. Knott’s BioCryst Pharmaceuticals BCRX Stock Holding History

David M. Knott’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,703
Closed -$312K – 148
2021
Q1 		$312K Sell
30,703
-188,758
-86% -$1.95M 0.13% 76
2020
Q4 		$1.64M Sell
219,461
-177,900
-45% -$917K 0.74% 36
2020
Q3 		$1.36M Hold
397,361
– – 0.8% 29
2020
Q2 		$1.89M Buy
397,361
+337,371
+562% +$1.35M 1.03% 25
2020
Q1 		$120K Buy
+59,990
New +$165K 0.08% 81

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

David M. Knott's BCRX Position: Q2 2021 in Review

David M. Knott sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 30,703 shares — an estimated $312K sold.

David M. Knott first reported a position in BCRX in Q1 2020 and held it in 5 quarters. The position peaked at $1.89M in Q2 2020. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • David M. Knott reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • David M. Knott sold 30,703 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $312K.
  • David M. Knott first reported a position in BioCryst Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • David M. Knott's BioCryst Pharmaceuticals position peaked at $1.89M in Q2 2020.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on David M. Knott's 13F filing for Q2 2021, filed 13 Aug 2021.